Monday, May 14, 2018
  • Bio Globalization Hits Home – Is Europe Caught in the Middle?

    Over nearly two decades, Bio€quity Europe has debated Europe’s relationship to the U.S. on scientific achievement, corporate leadership and access to capital. In 2018, Bio€quity Europe turns to the East, challenging both biotech innovators and investors to face the consequences of a fast-rising Asia on one side and the continuing leadership set by U.S. on the other.

5:30 PM to 5:45 PM

  • Bio€quity Europe Organizers Welcome
    City Hall / Pacificatiezaal
    • Mathias De Clercq, Senior Deputy Mayor and Deputy Mayor of the Port, Economy and Enterprise, City of Ghent
    • David Flores, President & CEO, BioCentury
    • Christophe Peeters, Vice Mayor, Retail, Festivities, Finance and Innovation, City of Ghent
    • Pam Putz, Managing Director, EBD Group
    • David Thomas, Senior Director, Industry Research and Policy Analysis at Biotechnology Innovation Organization

5:45 PM to 7:00 PM

  • Opening Session - Fireside Chat with Belgian Pathfinders on Resilience and Building Global Value
    City Hall / Pacificatiezaal

    Belgium has provided Europe with a host of pioneering biotechs, led by CEOs who have demonstrated resilience and stamina in the pursuit of homegrown innovation. What have these pathfinders learned, and how do these lessons apply as bio globalization hits home?  

    • Onno van de Stolpe, CEO, Galapagos 
    • Edwin Moses Ph.D, CEO, Ablynx 
    • Rudi Pauwels, Ph.D., Founder and Chairman of Strategy Committee, Biocartis NV, Former Founder, Chairman and CEO/CSO of Tibotec N.V.  

    In discussion with:

    • Karen Bernstein Ph.D, Chairman, BioCentury Inc.
    • Rudy Dekeyser, Ph.D, Managing Partner of LSP’s Health Economics Fund

7:00 PM to 8:30 PM

  • Welcome Reception
    City Hall, Ghent
Tuesday, May 15, 2018

8:00 AM

  • Bio€quity Europe Registration Opens

9:00 AM to 9:15 AM

  • Welcome Note
    Level 2, Zaal Rector Vermeylen

9:15 AM to 10:15 AM

  • Plenary 1 – Bio Globalization Hits Home: How Should Europe Respond?
    Level 2, Zaal Rector Vermeylen

    Asia’s rush into biotech provides new opportunity, new capital – and competition – for European innovators who have been focused on the U.S. What should European life science leaders be thinking about Asia’s commitment to invigorate life sciences innovation, prioritize regulatory modernization and build a high-energy startup ecosystem?

    Moderator: Josh Berlin, Executive Director, New Ventures, BioCentury

    • Roel Bulthuis, Head, M Ventures  
    • Franck Le Deu, Senior Partner & Head of Greater China Healthcare Practice, McKinsey
    • Nanna Lüneborg Ph.D., Partner, Novo Ventures
    • Jörg Neermann Ph.D, Partner, LSP
    • Antoine Papiernik, Chairman & Managing Partner, Sofinnova 
    • Patrick van Beneden, Partner, Healthcare, Gimv 

10:15 AM to 11:15 AM

  • Plenary 2 - Bio Globalization Hits Home: Where Can Europe Lead in Strategic R&D?
    Level 2, Zaal Rector Vermeylen

    Where is European science and biotech going to lead as genomics and regenerative medicine gather steam globally? 

    Moderator: C. Simone Fishburn Ph.D., Vice President & Executive Editor, BioCentury

    • Joanne Hackett Ph.D, CCO, Genomics England
    • Tim Haines, Managing Partner, Abingworth 
    • Jochen Maas DVM, Managing Director R&D Sanofi-Aventis Deutschland GmbH 
    • Hannes Smarason, Co-Founder and CEO, WuXi NextCode
    • John Tchelingerian, Ph.D., CEO, Promethera 
    • Nathalie ter Wengel M.D., European Head External Science and Innovation, Pfizer

11:00 AM to 11:10 AM

11:00 AM to 11:20 AM

11:10 AM to 11:20 AM

11:20 AM to 11:30 AM

11:30 AM to 12:30 PM

  • Biotech CEO Workshop 8.0: What European CEOs Need To Know To Attract U.S. Capital
    Level 2, Zaal Rector Vermeylen

    What do U.S. VCs need to see in order to put money into European Start Ups? This panel of VCs and executives debate what’s need to overcome ‘gating’ factors for U.S. investment in Europe

    • Carole Nuechterlein, Partner, Roche Venture Fund
    • Florian Fischer, CFO, Affimed N.V.
    • Ravi Mehrotra Ph.D., Partner, MTS Health Partners 
    • Henrijette Richter Ph.D., Managing Partner, Sofinnova Partners 

11:30 AM to 11:40 AM

11:40 AM to 11:50 AM

11:40 AM to 12:00 PM

11:50 AM to 12:00 PM

12:00 PM to 2:00 PM

  • Lunch and Networking Time
    Level 0, Kapitelzaal and Level 1

12:00 PM to 12:10 PM

12:00 PM to 12:20 PM

12:10 PM to 12:20 PM

12:20 PM to 12:40 PM

12:20 PM to 12:30 PM

2:00 PM to 3:10 PM

  • What Are Chinese Investors Looking for in European Assets?
    Room: Level 2+, Oude Infirmerie

    Inaugural China-Europe Showcase (Hosted by BioCentury and BayHelix)

    Flush with cash and driven by government reforms to invigorate life sciences innovation, Chinese VCs and corporate strategics are hunting for assets in Europe. These top investors explain how European biotechs can position themselves to take advantage of new financing opportunities from China. 

    • Sean Cao, Ph.D., Managing Director, C-Bridge Capital 
    • Leon Chen, Ph.D., CEO, 6 Dimensions Capital
    • Ting JIA "TJ", Ph.D., Managing Director, Hillhouse Capital Management
    • Kewen JIN, M.D., Managing Director, Serica Capital
    • Yuwen LIU, Founding Partner, Bohe Angel Fund
    • Huaizheng PENG, M.D., Ph.D., Managing Director, CMS Medical Venture Investment Ltd.

2:00 PM to 2:10 PM

2:00 PM to 2:20 PM

2:10 PM to 2:20 PM

2:20 PM to 2:30 PM

2:20 PM to 2:40 PM

2:30 PM to 3:30 PM

  • Is Europe Ready for Growth Capital Funds?
    Level 2, Zaal Rector Vermeylen

    To reach bellwether status, European biotechs need capital to grow beyond clinical proof of concept. But the dearth of specialist growth capital forces European innovators to look to the US, and increasingly toward pools of Asian money looking for commercial opportunities. Is it time for European funds to provide a homegrown solution, or cede the space to offshore money? Or does geography for growth capital matter less than early stage investments?

    Moderator: Paul Hadden, Managing Director, HealthCare Royalty Partners

    • Alain Baetens, Head of Listings, Belgium, Euronext
    • Chris De Jonghe Ph.D, Head of Life Sciences & Care, Group Manager Venture Capital, PMV 
    • Michele Ollier, M.D., Partner, Medicxi 
    • Gilles Nobécourt, Partner, Rothschild 
    • Greg Parekh Ph.D, Partner, New Rhein Healthcare Investors
    • Graziano Seghezzi, Managing Partner, Sofinnova Partners
    • Thomas Stockman, Managing Director, Healthcare, RBC Capital Markets

2:30 PM to 2:40 PM

2:40 PM to 3:00 PM

2:40 PM to 2:50 PM

2:50 PM to 3:00 PM

3:00 PM to 3:10 PM

3:00 PM to 3:20 PM

3:10 PM to 3:20 PM

3:15 PM to 4:30 PM

  • China Case Studies: Lessons Learned from European Deals
    Room: Level 2+, Oude Infirmerie

    Inaugural China-Europe Showcase (Hosted by BioCentury and BayHelix)

    This case study session dissects the drivers of the Chinese attraction to Europe, and how European biotech need to approach these new opportunities.

    Moderator: Jorge Santos da Silva Ph.D., Partner, McKinsey & Co.

    • Bianca Ahrens, Ph.D., Scientific Director, Business Development & Portfolio Management, MorphoSys AG
    • Stephan Lensky, Ph.D., COO/CBO, EpiMab Biotherapeutics Inc.
    • Ji LI, Ph.D., Global Head of Business Development, BeiGene Ltd.
    • Mai-Jing Liao, Ph.D., SVP, Head of Business Development and Portfolio Management, Harbour BioMed
    • Joan Shen, M.D., Ph.D., Head of R&D, I-Mab Biopharma 
    • Donald Wyatt, VP of Business Development &. Alliance Management, 3SBio Inc.

3:20 PM to 3:30 PM

3:20 PM to 3:40 PM

3:30 PM to 3:40 PM

3:40 PM to 4:00 PM

3:40 PM to 3:50 PM

3:45 PM to 5:15 PM

  • PRE-SEED SHOWCASE 1
    Level 2, Zaal Rector Vermeylen

    Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe 'judges' who provide high level feedback on their business plan, presentation and overall strategy.

    Moderator: Eric Pierce, Publisher, BioCentury 

    Judges:

    • Karen Bernstein Ph.D., Chairman, BioCentury
    • JR Rothe Ph.D, Managing Partner, LSP
    • Nico Vandervelpen, Managing Director Bioqube Ventures

3:50 PM to 4:00 PM

4:00 PM to 4:10 PM

4:00 PM to 4:20 PM

4:10 PM to 4:20 PM

4:20 PM to 4:30 PM

4:20 PM to 4:40 PM

4:30 PM to 4:40 PM

4:40 PM to 5:00 PM

4:40 PM to 4:50 PM

4:50 PM to 5:00 PM

5:00 PM to 5:10 PM

5:00 PM to 5:20 PM

5:20 PM to 5:40 PM

5:40 PM to 6:00 PM

6:00 PM to 6:20 PM

6:30 PM to 7:00 PM

  • Walk to Evening Reception

7:00 PM to 10:30 PM

  • Evening Reception and Entertainment

    Feestzalen Oude Vismijn
    Sint-Veerleplein 5, Ghent

Wednesday, May 16, 2018

8:00 AM

  • Registration Opens
    Het Pand, Ghent

9:00 AM to 10:10 AM

  • PRE-SEED SHOWCASE 2
    Level 2, Zaal Rector Vermeylen

    Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe 'judges' who provide high level feedback on their business plan, presentation and overall strategy.

    Moderator: Eric Pierce, Publisher, BioCentury

    Judges:

    • Sean Cao, Ph.D., Managing Director, C-Bridge Capital 
    • Emmanuel Lacroix, Ph.D. Senior Director, Venture Investments, UCB Ventures
    • Vanessa Malier, Partner, Kurma Partners

9:00 AM to 9:20 AM

9:00 AM to 9:10 AM

9:10 AM to 9:20 AM

9:20 AM to 9:30 AM

9:20 AM to 9:40 AM

9:30 AM to 9:40 AM

9:40 AM to 9:50 AM

9:40 AM to 10:00 AM

9:50 AM to 10:00 AM

10:00 AM to 10:10 AM

10:00 AM to 10:20 AM

10:10 AM to 10:20 AM

10:20 AM to 11:20 AM

  • Biotech Building Blocks Panel - How to go from Series B to Bellwether
    Level 2, Zaal Rector Vermeylen

    What C-level teams of European private biotechs need to put in place to become the next bellwether. This panel will discuss and debate what management teams of private companies need to put in place from shareholder and board level communications to control of assets and partnering. 

    Moderator: Jan De Kerpel Ph.D, Managing Director, Kempen & Co.

    Speakers: 

    • Joe Anderson Ph.D., CEO, Arix Bioscience
    • Gil Beyen, Chairman & CEO, Erytech Pharma
    • Arthur Franken, Partner, Gilde 
    • Hendrik Liebers Ph.D, CFO, Probiodrug AG
    • Marina Udier Ph.D, COO, Nouscom AG

10:20 AM to 10:40 AM

10:30 AM to 10:40 AM

10:40 AM to 11:00 AM

10:40 AM to 10:50 AM

11:00 AM to 11:20 AM

11:20 AM to 12:20 PM

  • New Pathways for financing EU startups
    Level 2, Zaal Rector Vermeylen

    Where early stage investors are playing in Europe what that could mean for your next fundraising round. Also how are investors prioritizing investment in brick and mortar companies versus more virtual models and spin-outs of deprioritized assets from Big Pharma?

    Moderator: Christina Takke Ph.D, Managing Partner, V-Bio Ventures

    • Jeanne Bolger, Ph.D, Vice President, Venture Investments, Johnson & Johnson Development Corp.
    • Johan Cardoen, Ph.D, Managing Director, VIB 
    • Frank Kalkbrenner, Ph.D, Head, Boehringer Ingelheim Venture Fund
    • Vanessa Malier, Partner, Kurma Partners
    • Erica Whittaker, Ph.D, Head of UCB Ventures

11:20 AM to 11:40 AM

11:40 AM to 12:00 PM

12:00 PM to 2:00 PM

  • LUNCH and Networking Time
    Level 0, Kapitelzaal and Level 1

12:00 PM to 12:20 PM

12:20 PM to 12:40 PM

2:00 PM to 3:20 PM

  • REGIONAL HOST SESSION
    Level 2, Zaal Rector Vermeylen

    Belgian Pitch Session

    Moderator: Gert Vanhees, Partner, Deloitte

    Companies: 

    • Agomab
    • Aphea.bio
    • VIPUN Medical
    • Others TBD

2:00 PM to 2:20 PM

2:20 PM to 3:00 PM

2:20 PM to 2:40 PM

2:40 PM to 3:00 PM

3:20 PM to 4:30 PM

  • Closing Reception